PubRank
Search
About
Peter Sehr
Author PubWeight™ 38.67
‹?›
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
The structural basis for cap binding by influenza virus polymerase subunit PB2.
Nat Struct Mol Biol
2008
4.33
2
Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins.
Clin Chem
2005
4.18
3
Suppression of non-specific binding in serological Luminex assays.
J Immunol Methods
2005
2.96
4
Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin.
J Natl Cancer Inst
2006
2.40
5
Residues in the HIV-1 capsid assembly inhibitor binding site are essential for maintaining the assembly-competent quaternary structure of the capsid protein.
J Biol Chem
2008
1.61
6
Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination.
Clin Cancer Res
2004
1.51
7
Seroprevalence of 34 human papillomavirus types in the German general population.
PLoS Pathog
2008
1.44
8
Recognition of 2'-O-methylated 3'-end of piRNA by the PAZ domain of a Piwi protein.
Structure
2011
1.37
9
Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types.
J Gen Virol
2008
1.35
10
Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins.
Cancer Res
2003
1.24
11
Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice.
J Virol
2003
1.12
12
Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients.
J Cancer Res Clin Oncol
2003
1.10
13
Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate.
PLoS One
2012
1.08
14
Absence of SV40 antibodies or DNA fragments in prediagnostic mesothelioma serum samples.
Int J Cancer
2007
1.07
15
The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies.
Virology
2010
1.04
16
Presence of DNA of human papillomavirus 16 but no other types in tumor-free tonsillar tissue.
J Clin Microbiol
2005
0.97
17
Antibody responses to 26 skin human papillomavirus types in the Netherlands, Italy and Australia.
J Gen Virol
2009
0.97
18
Tumor suppressive activity of a variant isoform of manganese superoxide dismutase released by a human liposarcoma cell line.
Int J Cancer
2006
0.93
19
New 7-methylguanine derivatives targeting the influenza polymerase PB2 cap-binding domain.
J Med Chem
2013
0.89
20
Interaction of the Rho-ADP-ribosylating C3 exoenzyme with RalA.
J Biol Chem
2002
0.87
21
Human papillomavirus type 16 E2- and L1-specific serological and T-cell responses in women with vulval intraepithelial neoplasia.
J Gen Virol
2003
0.86
22
Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial.
J Infect Dis
2013
0.85
23
Structural basis for targeting the chromatin repressor Sfmbt to Polycomb response elements.
Genes Dev
2013
0.85
24
A novel peptide motif binding to and blocking the intracellular activity of the human papillomavirus E6 oncoprotein.
J Mol Med (Berl)
2008
0.83
25
Modification of HPV 16 E7 genes: correlation between the level of protein expression and CTL response after immunization of C57BL/6 mice.
Vaccine
2005
0.83
26
Automated high-throughput RNAi screening in human cells combined with reporter mRNA transfection to identify novel regulators of translation.
PLoS One
2012
0.79
27
A virosomal immunization strategy against cervical cancer and pre-malignant cervical disease.
Antivir Ther
2006
0.79
28
Antibodies against Gag are diagnostic markers for feline foamy virus infections while Env and Bet reactivity is undetectable in a substantial fraction of infected cats.
Virology
2005
0.76